<--- Back to Details
First PageDocument Content
Oncology / Chemotherapy-induced nausea and vomiting / Chemotherapy / 5-HT3 antagonist / Ondansetron / Aprepitant / Ginger / Adjuvant therapy / Management of cancer / Medicine / Antiemetics / Cancer treatments
Oncology
Chemotherapy-induced nausea and vomiting
Chemotherapy
5-HT3 antagonist
Ondansetron
Aprepitant
Ginger
Adjuvant therapy
Management of cancer
Medicine
Antiemetics
Cancer treatments

An upper limit for macromolecular crowding effects

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 329,98 KB

Share Document on Facebook

Similar Documents

Chemotherapy-induced nausea and vomiting / Oncology / Drug discovery / 5-HT3 antagonist / Cisplatin / Medicine / Chemistry / Antiemetics

P11444 - ASCO2014 MEC and HEC

DocID: 1a4Ek - View Document

Oncology / Chemotherapy-induced nausea and vomiting / Drug discovery / Organochlorides / Prodrugs / 5-HT3 antagonist / Cyclophosphamide / Chemotherapy / Vomiting / Medicine / Chemistry / Antiemetics

P11444 - ASCO2014 MEC and HEC

DocID: 19OCx - View Document

Antiemetics / Abdominal pain / General practice / Syndromes / Ketones / Irritable bowel syndrome / Diarrhea / Ramosetron / 5-HT3 antagonist / Medicine / Health / Gastroenterology

Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella

DocID: 19AF1 - View Document

Chemotherapy-induced nausea and vomiting / Cyclophosphamide / 5-HT3 antagonist / Chemotherapy / Medicine / Oncology / Antiemetics

P11444 - ASCO2014 MEC and HEC

DocID: 199Dl - View Document

Alkylating antineoplastic agents / Antiemetics / Chemotherapy-induced nausea and vomiting / Prodrugs / Cyclophosphamide / 5-HT3 antagonist / Chemotherapy / Cisplatin / Medicine / Chemistry / Oncology

P11444 - ASCO2014 MEC and HEC

DocID: 1987o - View Document